Roles of neuroimaging markers and biomarkers in cerebral small vessel disease and their associations with cognitive function
Authors:
Open Access
- 1 May 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1483842
Abstract
Cerebral small vessel disease (CSVD) is an intracranial vascular disorder caused by the impairment of cerebral microvessels, with various pathological backgrounds. Currently, a clear and definitive set of diagnostic criteria for CSVD continues to be elusive, and its diagnosis relies primarily on medical history, clinical presentation, brain imaging features, and genetic detection. In clinical practice, no single biomarker was identified. Previous studies have delved into various biomarkers in CSVD and their relationships with cognitive functions, yielding promising candidates. However, drawing a unified and conclusive consensus poses a challenge due to the inherent heterogeneity in research. Therefore, we reviewed the current progression of CSVD biomarkers and their relationship with cognitive functions, mainly including neuroimaging markers and biomarkers related to cerebrospinal fluid (CSF), as well as blood to assist clinicians in diagnosis.Keywords
This publication has 96 references indexed in Scilit:
- CADASIL Affects Multiple Aspects of Cerebral Small Vessel Function on 7T‐MRIAnnals of Neurology, 2022
- Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markersAlzheimer's & Dementia, 2021
- Advances in Understanding the Pathophysiology of Lacunar StrokeJAMA Neurology, 2018
- Large Perivascular Spaces Visible on Magnetic Resonance Imaging, Cerebral Small Vessel Disease Progression, and Risk of DementiaJAMA Neurology, 2017
- Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosisAnnals of Neurology, 2017
- Tau positron emission tomographic imaging in aging and early Alzheimer diseaseAnnals of Neurology, 2015
- Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly IndividualsJAMA Neurology, 2015
- Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer DiseaseJAMA Psychiatry, 2014
- Lipoprotein‐associated phospholipase A2 is associated with risk of dementiaAnnals of Neurology, 2005
- Novel Risk Factors for Systemic AtherosclerosisJAMA, 2001